The prognostic value of EpCAM-positive CTCs has been confirmed for further tumor entities, including lung cancer [86], advanced ovarian cancer [87], gastric cancer [88], colorectal cancer [89], and head and neck squamous cell carcinoma (HNSCC) [90]. This evidence concerns the gene EPCAM and head and neck squamous cell carcinoma.